Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials

BACKGROUND: Zoledronic acid (ZA) does not improve the overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC); however, little is known about the efficacy of ZA in to hormone-sensitive prostate cancer (HSPC), metastatic hormone-sensitive prostate cancer (mHSPC), and non- met...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chiwei, Lin, Mandi, Yu, Daocheng, Qin, Weiting, Zhou, Jianfu, Guo, Lang, Huang, Renlun, Fan, Xinxiang, Xiang, Songtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499269/
https://www.ncbi.nlm.nih.gov/pubmed/36137135
http://dx.doi.org/10.1371/journal.pone.0275176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499269/
https://www.ncbi.nlm.nih.gov/pubmed/36137135
http://dx.doi.org/10.1371/journal.pone.0275176

Ejemplares similares